Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University.

In this episode, we covered:

•⁠  ⁠We covered the recent approval of durvalumab in limited stage setting post chemoRT.

•⁠  We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib.

•⁠ Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab

•⁠  Talked about logistical issues and uptake of Tarlatamab post approval.

Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!